In the past several years there has been increasing concern about the risk of transmitting virus infections by intravenous gammaglobulin. Initial studies focused on the risk of Hepatitis b; when the AIDS virus was identified it proved to be sensitive to the ethanol used in the processing of intravenous gammaglobulin so that there never has been a case a HIV transmitted by gammaglobulin. Unfortunately, the Hepatitis C virus is not so sensitive, and in 1994 there was an outbreak of Hepatitis C caused by one of the licensed preparations of gammaglobulin. Several strategies have been developed to decrease the risk of transmitting virus infections. Most have employed a solvent and detergent step to inactivate all known enveloped viruses. This process is not effective against other types of viruses. Armour Pharmaceuticals has developed a liquid intravenous gammaglobulin preparation that is heat pasteurized to inactivate a wide variety of known viruses. This is a multicenter, randomized double-blind, Phase II study comparing the new heat-pasteurized RPR 109413 to the licensed preparation Gamimune-N. In the first six month phase two of three patients are randomized to receive the RPR product and the other third receives Gamimune-N. In the second six months all patients receive the RPR gammaglobulin without blinding. All patients are treated at the same dose and frequency that they were treated prior to the study. Efficacy is evaluated by use of patient diaries, use of medications, and days of hospitalization or days missed from work or school. Safety is monitored by recording clinical reactions to the infusions and by measuring serum chemistries and blood counts.
| Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201 |
| Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445 |
| Denson, Lee A; McDonald, Scott A; Das, Abhik et al. (2017) Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants. Am J Perinatol 34:240-247 |
| James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4 |
| Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628 |
| Phelps, Dale L; Ward, Robert M; Williams, Rick L et al. (2016) Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res 80:209-17 |
| Archer, Stephanie Wilson; Carlo, Waldemar A; Truog, William E et al. (2016) Improving publication rates in a collaborative clinical trials research network. Semin Perinatol 40:410-417 |
| Ahmed, Zuhayer; Prasad, Indrajit; Rahman, Hafizur et al. (2016) A Male with Extreme Subcutaneous Insulin Resistance: A Case Report. Rom J Diabetes Nutr Metab Dis 23:209-213 |
| Barroso, Julie; Leserman, Jane; Harmon, James L et al. (2015) Fatigue in HIV-Infected People: A Three-Year Observational Study. J Pain Symptom Manage 50:69-79 |
| Stafford-Smith, Mark; Li, Yi-Ju; Mathew, Joseph P et al. (2015) Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci. Kidney Int 88:823-32 |
Showing the most recent 10 out of 128 publications
